NCT06569784View on ClinicalTrials.gov

Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

July 2, 2024

Study Completion Date

October 30, 2024

Conditions
Healthy
Interventions
DRUG

[14C]HSK31858

A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Xizang Haisco Pharmaceutical Co., Ltd

INDUSTRY